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Abstract The article outlines a history of the concept of
‘‘disease-modifying antirheumatic drugs’’ or DMARDs—
from the emergence in the 1970s of the idea of drugs with
decisive long-term effects on bone erosion in rheumatoid
arthritis (RA), through the consolidation and popularisation
in the term DMARD in 1980s and 1990s. It then examines
the usage of the terms ‘‘remission-inducing drugs’’ (RIDs)
and ‘‘slow-acting anti-rheumatic drugs’’ (SAARDs), which
for some years offered competition to the term DMARDs,
thus underscoring the contingency of the establishment of
DMARD as a word. Finally, it juxtaposes the apparently
spontaneous emergence of the three terms DMARD,
SAARD and RID, and the disappearance of the latter two,
with a failed attempt in the early 1990s to replace these
terms with the new term ‘‘disease-controlling antirheumatic
treatment’’ (DC-ART). The analysis highlights the para-
doxical qualities of the DMARD concept as robust albeit
tension ridden, while playing down the role of identified
individuals and overarching explanations of purpose.
Keywords DMARD  SAARD  RID  DC-ART 
Drug classes  Rheumatology  History  Anthropology
A history of the term DMARD
Drugs designated as disease-modifying antirheumatic
drugs (DMARDs) were established as mainstream an-
tirheumatic treatments at different moments in time:
injectable gold in the 1930s, hydroxychloroquine in the
1950s, azathioprine in the 1960s, sulphasalazine and
methotrexate in the mid-1980s, the selectively im-
munomodulating drugs or so-called biological DMARDs,
from 1998 on. The histories of the different drugs have
been well documented.1 Yet the category that came to
contain these drugs emerged at a separate moment in the
midst of it all. Like all categories and concepts with which
people equip themselves, it not only helps thinking and
talking, but also fundamentally circumscribes and guides
these endeavours, making certain thoughts thinkable and
others unthinkable. The way in which the category of
DMARDs operates, in rheumatology as in inflammophar-
macology, therefore has profound implications. Even so,
little has been written about its development and history.
This article shall contribute to fill that void.
The source of the Nile or its course
At the Norwegian hospital where in 2012 I did ethno-
graphic field research, the term DMARD seemed to be
taken for granted and used rather as a natural category,
with little said or done implying that it had a history. As
written sources could say little about its origin, I once
asked the chief consultant if she knew how the term had
appeared:
I think it is really just a result of some so-called
experts who have been sitting and talking and needed
a name for it, and then realised that, well, perhaps
that was a suitable name.
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That did not seem an unlikely explanation, and looking
for those hypothetical experts and the place, they might have
been sitting and talking, provided a point of departure for the
analysis that follows. I collected testimonies from several
authors of publications where I could document early usage
of the term, and fragment by fragment, contours of an early
history of the term could be pieced together: the purpose of
introducing a concept to describe drugs that might be ca-
pable of altering the long-term course of the disease had
been to distinguish these drugs from the NSAIDs, which
were known only to affect the symptoms. This boundary
making had remained the main function of the term
throughout the late 1970s and early 1980s when many
pharmaceutical companies, often with separate discovery
programmes for NSAIDs and DMARDs, were working to
create and develop new drugs. Any one particular moment
for the birth of the concept did, however, evade me, and one
source’s suggestion that the concept appeared with the in-
troduction of penicillamine has not been possible to verify.
One need not always, however, push hard for an indi-
vidual progenitor or for critical contexts and moments of
creation: there may be none. Even where an individual
progenitor can be singled out, as in the case of Whitehouse
and the concept of ‘‘non-steroidal anti-inflammatory
drugs’’ (see Buer 2014), and where information about the
progenitor’s motivation for coining the term is available,
this is of only limited use for a broader analysis, as the
decisive mechanism behind the widespread use of a term
like DMARD cannot be of one expert’s judgement or de-
cision alone, but must lie in the repeated judgments and
decisions of a range of different social actors. Following
Barth (1990), our approach here will therefore be to see the
development of the term as an ‘‘inadvertent, cumulative
effect of activity to which actors [have been] propelled by
perceived necessities or advantages attaching to other
aspects of their activities’’, i.e. to see the emergence of the
concept as originating from the repeated choices of a
multitude of actors to use the term, not because they
wanted such a term to emerge or gain currency and not
because of sympathy with the intentions of the term’s un-
known, hypothetical progenitor, but because the
circumstances in which all these actors acted and their
immediate concerns made the term appear as purposeful.
Considerations of method
In order to create a more precise sketch of the development
of the term DMARD, I proceeded (as with the term
NSAIDs, cf. Buer 2014) by means of searches in the
PubMed databases for examples of early use.2 This
approach does have certain evident shortcomings. First, the
database does not contain full-text articles, consequently
appearances of an item in the body text of the publications
is not searchable. Also the database is not comprehensive;
many older or otherwise marginal publications have not
been registered. A PubMed search will thus only be able to
identify use in publications which have been registered and
where the sought-for term appears not in the body text of
the publication, but in its title, its list of keywords, etc.
Second, sought-for terms may well have been coined in a
different context than that of research publishing and had
their use established in those other contexts well before
they started appearing in scientific journals. They may have
emerged and found their shape in private thought and
collegial discussions, at hospitals and universities and in
pharmaceutical companies, and then, by haphazard or by
gradual progression, they may have come to be perceived
as useful for expressing certain ideas in public discussions,
at symposia or conferences—and ultimately in scientific
articles. A first mention of a term in an academic publi-
cation is thus only a hint of the term’s history, and an
appearance of the phrase in a PubMed search may merely
be the first searchable appearance of the phrase in PubMed.
It is therefore necessary to consider the findings as
indicative rather than evidential.
Even so, the data generated by the PubMed searches that
I performed do tell a story about the use and development of
the term. As we shall see, they tell a story of several terms
competing to describe the same drugs and of one term ul-
timately supplanting the others. The data also reveal that the
development of this term followed the same phases of de-
velopment as the concept of NSAIDs had done some years
earlier (see Buer 2014): the idea of drugs capable of pre-
venting bone erosion in RA first developed in malleable
descriptive phrases giving shape to the concept of ‘‘disease-
modifying’’ drugs. The phrase then found a solid shape as a
concept-category expressed by a fixed formula: ‘‘disease-
modifying anti-rheumatic drugs’’. From that formula spun
an initialism (i.e. an abbreviation formed from initial let-
ters), ‘‘DMARD’’, which by time got established as an
acronym, thus becoming word in its own right. The data
trace the contours of a development where drug categories
destined to last emerged as such in the day-to-day struggles
of researchers, manufacturers, salesmen, physicians, bu-
reaucrats and patients to conceptualise and put into words
the fragile and sometimes conflicting connections between
disease and drug, cause and effect, and hope and reality.
The phrase ‘‘disease-modifying’’
The earliest use of the term ‘‘disease-modifying’’ that the
PubMed (‘‘all fields’’) search identified was the article
‘‘Cyclophosphamide, gold and penicillamine—disease-
2 For the different terms, I performed ‘‘text word’’ search for
publications where the term was included (on 28 November 2014).
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modifying drugs in rheumatoid arthritis—tailored dosage
and ultimate success’’ (Gumpel 1976, see Fig. 1). A closer
look at the usage of the phrase in that article makes it clear
that that phrase was already established when Gumpel
chose to use it in his article. In PubMed, however, there is
meagre evidence of its use at the time. Except for an article
about influenza vaccines (Jovanovic et al. 1979), I identi-
fied no other publications containing the phrase until the
beginning of the 1980s. Then, however, this changed.
Three publications from 1980 contained the phrase ‘‘dis-
ease-modifying’’ in either title or abstract (Hunneyball
1980; McConkey et al. 1980; Bunch and O’Duffy 1980).
Although my search revealed no publications from 1981
containing the phrase ‘‘disease-modifying’’, the phrase
reappeared in five publications from 1982 (van Wanghe
and Dequeker 1982; Barnes 1982; Paulus 1982; Whisnant
and Pelkey 1982; Rainsford 1982). From then on, the fre-
quency increased: from 1983, 10 publications; 14 from
1984, 13 from 1985 and so on. Clearly, between 1980 and
1982, something had happened: the idea of disease-
modifying drugs had gained momentum.
Fixed phrase and abbreviation
A closer examination reveals that at approximately that
time, barely preceding the sharp rise in frequency observed
from 1982 on, the concept underwent two interconnected
transformations which resulted in a cementation of the
term: first, the idea of disease-modifying drugs ceased to be
expressed in varying descriptive phrases open to reformu-
lation and became fixed as formula, the concept-phrase
‘‘disease-modifying antirheumatic drugs’’. Second, this
fixed concept-phrase engendered an initialism:
‘‘DMARD’’. Both transformations are tangible in the jux-
taposition of the article ‘‘An overview of benefit/risk of
disease-modifying treatment of rheumatoid arthritis as of
today’’ (Paulus 1982), which is the earliest appearance of
the initialism DMARD that I have documented, and the
review ‘‘Recent developments in disease-modifying an-
tirheumatic drugs’’ (Hunneyball 1980) published only
2 years earlier. In Hunneyball’s text, from 1980 the phrase
that he employed to refer to the category still seemed
malleable: while he used the phrase ‘‘disease-modifying
antirheumatic drugs’’ in the title, he used the phrase ‘‘non-
steroidal disease-modifying drugs’’ in the body text.3
Contrasting this dynamic play of semantics in Paulus text,
published 2 years later, the phrase appears as fixed in the
shape it retains today. It was from this fixed phrase that the
initialism DMARD spun. Yet, among the numerous ini-
tialisms in Hunneyball’s text, the initialism DMARD did
not figure; the malleability which the phrase of origin still
retained did not allow for that. In Paulus text, by contrast,
the initialism DMARD is aptly used in replacement of the
full phrase (see Fig. 2).
DMARD as a word
The next decisive change that we can observe from the
PubMed search data is the establishment of the initialism
Fig. 1 Earliest appearance of
the expression ‘‘disease-
modifying’’ in the PubMed
database. With permission from
Gumpel (1976), Rheumatology,
Oxford University Press
Fig. 2 This passage from Paulus’ (1982) article is the earliest use of
the initialism DMARD that I documented. Typically for initialisms,
the term follows in parenthesis after the full phrase. With permission
from Paulus, Annals of the Rheumatic Diseases, BMJ Publishing
Group Ltd
3 Note that the inclusion of the term ‘‘non-steroidal’’ in the phrase
works to exclude corticosteroids from the category, just as they were
excluded from the category ‘‘non-steroidal anti-inflammatory drugs’’.
The concept of DMARD eventually came to be understood as
excluding steroids, albeit implicitly.
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DMARD as an acronym, i.e. as a proper word developed
along similar lines as those the word ‘‘laser’’ followed,
shooting off from the phrase ‘‘light amplification by
stimulated emission of radiation’’. This transition happened
gradually, and any attempt to locate it to a fixed date risks
being both futile and misleading. Nevertheless, as this
development necessitated that the users of the initialism
DMARD had become so familiar with its meaning that the
original phrase became superfluous, the leap to wordhood
can be observed in textual evidence when the phrase
‘‘disease-modifying antirheumatic drug’’ ceases to precede
the initialism, and the term ‘‘DMARD’’ starts to figure
independently from the concept-phrase. Further, the ap-
pearance of the stand-alone acronym in the title of
scientific publications is a good indication as to when such
use had become commonplace.
The earliest example of a title containing the term
DMARD that I documented was a publication in Danish:
‘‘Behandling af patienter med reumatoid arthritis med
DMARD (disease modifying anti-rheumatic drugs)’’
(Halberg 1984). In its title, the full phrase figured together
with the acronym, albeit in parenthesis and in reverse order
to that which would have been the case with an initialism.
This use indicates that DMARD was about to be estab-
lished as a word but also that the acronym still was
considered to require exegesis—at least in the Danish
context. The fact that that publication was the only one
from the 1980s which has the isolated acronym
‘‘DMARD’’ in its title may indicate that Halberg’s use was
somewhat premature or precursory.
The next publication in which title the term DMARD
figures as acronym marks a more significant beginning.
This was the article ‘‘Safety issues related to DMARD
therapy’’ (Fries 1990, see Fig. 3), which was followed
shortly by ‘‘Occurrence of neoplasia in patients with
rheumatoid arthritis enrolled in a DMARD Registry’’
(Matteson et al. 1991). From that moment and throughout
the 1990s and 2000s, the use of the acronym DMARD in
the titles of scientific publications multiplied. A PubMed
search on 17.12.2014 identified 273 such titles. A Google
search for the word4 gave 475,000 results.
The term DMARD had gained currency as a word. The
term DMARD had been chosen again and again to create
this effect, which implies that for some reason this term
was perceived to best answer the cognitive and commu-
nicative challenges of the most numerous or the most
influential social actors. A comparison with the develop-
ment of two other terms which competed to describe the
same category of drugs reveals the contingency of that
development.
Competing terms: RID and SAARD
The term DMARD was but one of the several terms, each
highlighting different properties, which competed to de-
scribe the same drugs. It was the term that gained currency
the fastest and the term that remained in use while the
alternatives did not.
One concept which was introduced to categorise the
same drugs as did DMARDs was ‘‘remission-inducing
drugs’’ or RIDs.5 An ‘‘all fields’’ PubMed search for ‘‘re-
mission-inducing drugs’’ (on 28 November 2014) gave a
list of 53 texts, published between 1980 and 2010, 42 of
which pertained to arthritis. Out of these 42, only eight
publications, published between 1980 (Anastassiades 1980)
and 1987 (Hansen et al. 1987), had the term ‘‘remission-
inducing drug’’ in their title, and the initialism ‘‘RID’’
figured in only one title, but not as a proper word; RID
appeared in parentheses following the full phrase ‘‘remis-
sion-inducing drugs’’, a use which is indicative of status as
initialism. No publications had ‘‘RID’’ as a stand-alone
acronym in its title.
A second competing term was ‘‘slow-acting anti-
rheumatic drugs’’ or SAARDs. PubMed searches revealed
47 publications that figured the phrase ‘‘slow-acting an-
tirheumatic’’ or ‘‘slow-acting anti-rheumatic’’ in their title.
The earliest article identified in the search was ‘‘To assess
the effect of slow-acting anti-rheumatic drugs in man’’
Fig. 3 Fries, title page, first title containing acronym DMARD. With
permission from Fries (1990), The Journal of Rheumatology
Fig. 4 Earliest use of the term ‘‘slow-acting anti-rheumatic drugs’’
identified in PubMed. With permission from Vischer (1979), Agents
Actions Suppl, Springer Science?Business Media
4 For DMARD or DMARDs, ‘‘any language’’, on 28 December 2014.
5 This term is likely to have migrated from oncology, as the earliest
appearance in PubMed of the term ‘‘remission-inducing drugs’’ is a
paper on chemotherapy in leukaemia (Perk et al. 1975).
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(Vischer 1979, see Fig. 4), followed by ‘‘Slow-acting an-
tirheumatic drugs’’ (Mowat 1982). The last publication
identified was ‘‘New treatments for rheumatoid arthritis.
Available and upcoming slow-acting antirheumatic drugs’’
(Fye 1999).6 After 1999, no authored publications in
English registered in the PubMed database had the phrase
‘‘slow-acting antirheumatic drug’’ in its title.
As for the term’s initialism (SAARD), it figured in the
title of three publications (Danis et al. 1991; Capell and
Brzeski 1992; van Gestel et al. 1997). In all three cases, the
term figured in parenthesis following the full phrase ‘‘slow-
acting anti-rheumatic drugs’’, indicative of use as initial-
ism; it was not standing alone as an independent word, as
the term DMARD had come to do (Fig. 5).
Judging from these data, neither ‘‘RID’’ nor ‘‘SAARD’’
attained wordhood like ‘‘DMARD’’ did. The phrase ‘‘re-
mission-inducing drugs’’ never even became a robust
concept; it survived for some years as a standardised de-
scriptive phrase, but went out of use as it became evident
that the drugs did not induce remission (see Capell and
Brzeski 1992; Scott et al. 1987). The term ‘‘slow-acting
anti-rheumatic drugs’’ gained a more widespread use. Yet it
was less popular and less robust than the term DMARD,
and it did not develop as far towards becoming a word, as
testified by the absence of titles with the stand-alone
acronym SAARD in PubMed. Also, for both ‘‘RID’’ and
‘‘SAARD’’, their usage, as indicated by their appearance in
titles in PubMed, fell within limited time frames
(1980–1987 for RID, 1979–1999 for SAARD).
An effort to replace the term
In the early 1990s, more than a decade had passed since the
use of the term ‘‘disease-modifying antirheumatic drug’’
had become established. The 4th joint meeting of the
WHO/ILAR7 Task Force on Rheumatic Diseases proposed
to replace the terms DMARD and SAARD. The proposed
new classifications were announced in a piece co-authored
by three professors of medicine from USA, UK and Aus-
tralia (Paulus et al. 1992), giving broad geographical
mooring.
According to the authors, the only characteristic that it
had been demonstrated that the drugs referred to as SAARDs
or DMARDs shared, in addition to their being ‘‘somewhat
slower acting’’, was their ability to provide symptomatic
relief in RA (Edmonds et al. 1993b). This, we recall, was
precisely the effect profile that the category was used to
demarcate against. The ‘‘belief’’, the authors wrote, that
these drugs influenced the course of the disease was based on
positive reports on the effect on radiologic progression and
joint damage of some of these drugs, while in fact even those
data were ‘‘by no means straightforward’’ (Edmonds et al.
1993b). In fact, despite the considerable development of
new drugs, evaluation of DMARD/SAARD treatment in RA
revealed ‘‘disappointing long-term results’’ (Edmonds et al.
1993b).
On this ground, the authors argued that the inter-
changeable use of SAARDs and DMARDs to describe the
drugs was inconsistent and contributed to confusion about
the actual properties of the drugs (Edmonds et al. 1993b).
They proposed an adaptation of the drug classes to fit facts
which testing had revealed, i.e. they advocated an adapta-
tion to a situation where disease-modifying drugs had not
yet developed but were expected to do so.
Classification proposed (1992)
The proposal introduced two new categories: symptom-
modifying antirheumatic drugs (S-MARDs) and disease-
modifying antirheumatic drugs (D-MARDs, see Fig. 6).
To the category, S-MARD would be assigned drug
therapies that had been proven to have effect on the
symptoms of the disease—i.e. pain, inflammatory activity,
etc.—but which had not been proven to alter the course of
the disease and prevent or delay bone destruction. The
category ‘‘disease-modifying anti-rheumatic drugs’’
(shortened D-MARDs, with a hyphen) would comprise
drugs with proven capacity to alter the course of the disease
(i.e. preventing bone erosion).
Fig. 5 Title page of one of the three publications, in PubMed that had
the initialism SAARD in their title. With permission from Capell and
Brzeski (1992), Annals of the Rheumatic Diseases, BMJ Publishing
Group Ltd
6 The search identified two more publications after this date,
disregarded in this analysis on the ground that the one had no authors
(NN 2001), while the other was in French (Van Linthoudt and Gerster
2004). Similarly, one publication in German (Wollin and Menninger
1997) has been disregarded in the account on RIDs. 7 International League Against Rheumatism.
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Updated proposal (1993)
A more elaborate proposal was published the following
year (Edmonds et al. 1993b). Taking into account the
emergent fact that management of RA ‘‘relates as much to
an overall management strategy or drug combination as to
a single agent’’, the most significant modification from the
previous year’s proposal was the substitution of the term
‘‘D-MARD’’, with the term ‘‘DC-ART’’ or ‘‘disease-con-
trolling antirheumatic therapy’’ (see Fig. 7). This was
intended to encourage research on combination treatment
programs in addition to single drugs (Edmonds et al.
1993b). Taking the place of DMARDs in the classificatory
system, the concept would encompass ‘‘a drug or a strategy
that prevents or significantly limits anatomic damage and
maintains function and well-being at follow-up periods of
5, 10, 20 years, and even longer’’ (Edmonds et al. 1993b).
How the new system would work
In contrast to the classification that it was intended to
supplant—where any one drug belonged to one category,
the new proposed classificatory system would be em-
ployed as stepwise progressive criteria against which both
existing and new drugs could be measured. Any an-
tirheumatic drug for which symptomatic effect was
demonstrated would be given an initial approval as SM-
ARD (Paulus et al. 1992). With a provisional status as
SM-ARD, the drug could be used in the treatment of RA
and over time proves its capacity to alter the course of the
disease and earn the designation as ‘‘disease-controlling
antirheumatic therapy’’, DC-ART. As a solution to the
practical problem arising from the fact that one could not
know what effect a newly developed drug would have 20
or 30 years ahead, classification included gradually pro-
gressing criteria towards long term: ‘‘…the use of this
classification should invariably indicate the period over
which such activity has been demonstrated, e.g., 1-year
DC-ART, 2-year DC-ART, 5-year DC-ART, etc.’’ (Ed-
monds et al. 1993b).
Outcome: an empty category and devaluation of all
existing DMARDs
As no existing drugs had yet been proven to have the kind
of effects one had hoped the disease-modifying drugs
would have, the proposed criteria thus implied that all
existing drug therapies—NSAIDs, corticosteroids and even
the drugs hitherto known as DMARDs, RIDs or
SAARDs—would be reclassified as symptom-modifying
antirheumatic drugs of categories I, II and III, respectively
(Paulus et al. 1992; Edmonds et al. 1993b).
This could be seen as a setback, but the proponents of
the initiative hoped that the new classification should fa-
cilitate design and implementation of clinical trials and
stimulate development of new drugs (Edmonds et al.
1993b):
The proposed classification is logical and should
make antirheumatic drug development and testing
more efficient. (…) The stringency of the classifica-
tion should encourage those concerned with drug
manufacture and rheumatic disease therapy to de-
velop new agents and new strategies that aspire to
DC-ART classification.
The stepwise progression in particular, they argued,
would make it easier for drug developers and manufac-
turers ‘‘to show that a new drug is effective’’ (Edmonds
et al. 1993b). The other side of the coin, from the per-
spective of the providing part, was that it would be much
harder to get a drug recognised as a DC-ART than it had
been to get it accepted as a DMARD. From a health and
safety perspective, one might argue that both these effects
were favourable.
Problems
There were, however, several important challenges related
to the new classification of DC-ARTs, and although the
system was ratified by both ILAR and WHO (Edmonds
Fig. 6 Classification of antirheumatic drugs proposed in 1992. With
permission from Paulus et al. (1992), Arthritis and Rheumatism, John
Wiley and Sons
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1994a), it soon ran into problems. There were economical
and practical challenges relating to trials that the propo-
nents of the initiative had foreseen: ‘‘Trials for
classification as DC-ART will be complex, time-consum-
ing, labor-intensive, and expensive’’ (Edmonds et al.
1993b). Also, before tests could start, problems would have
to be handled. These pertained to method and to criteria for
judging the effect of drugs over time, as well as to the
perceived need of stratifying patients (Edmonds et al.
1993b). Several publications followed (Edmonds et al.
1993a; Edmonds 1994b). Soon signs emerged that the
initiative had got caught in the technicalities inherent in the
new categories (Edmonds and Bosi Ferraz 1994):
Given the heterogeneity of rheumatoid arthritis (…),
it seems likely that some therapeutic regimens will
satisfy DC-ART criteria to different degrees in dif-
ferent strata of patients with RA. Since it entails its
own problems, it is recommended that the value and
feasibility of stratification be evaluated before any
attempt to design a DC-ART trial.
After this, it seems that the initiative soon stalled. The
authors had correctly enough foreseen that the classifica-
tion would need to be promoted though close work ‘‘with
the international rheumatology community, regulatory
agencies, and industry, towards their acceptance and use in
drug development, testing, and regulatory control’’ (Ed-
monds et al. 1993b). This did not fare as well as it was
hoped. Professor John Edmonds recalled some 20 years
later:8
Perhaps like so many other things transacted at WHO
meetings, it was endorsed, published and ignored. I
expect that for a new classification to have gained
currency, it would have to have been taken up by
powerful American groups—but that didn’t happen
and the status quo was safely maintained. In any
event, it was not greatly important.
I have found little evidence of later use in RA.9 Just as
the general silence gives a hint as to the destiny of the new
classification, so does the tone of one of the few mentions
of the initiative in later literature: in his historical review of
old and new antirheumatic drugs, John P. Case referred to
the initiative as a recommendation to use ‘‘yet another
descriptive term’’, while adding: ‘‘…whether such a purely
semantic approach to the question adds much is certainly
debatable’’ (Case 2001a).
Concluding remarks
Ten years prior to the WHO/ILAR meeting where the new
classifications were proposed, Anastassiades had warned
about the risks of unchecked introduction of new DMARDs
(Anastassiades 1980):
One cannot but be concerned about the possibility of
a therapeutic hydra, with a decline in popularity of
one remission-inducing drug because of serious side-
effects serving as an impetus for the evaluation of
many other agents, whose significant toxicity might
be appreciated only gradually.
Far from being a ‘‘purely semantic approach’’, as case
wrote in 2001, the initiative to introduce new drug cate-
gories to supplant the problematic SAARD/DMARD
concept was a forceful attempt to align the medical map
Fig. 7 Revised proposal for classification of antirheumatic therapies. With permission from Edmonds et al. (1993b), Arthritis and Rheumatism,
John Wiley and Sons
8 Personal communication (8 January 2015).
9 There is, however, some evidence of later use of this terminology in
publications pertaining to the management of ankylosing spondylitis
(AS): for instance, an international specialist group (ASAS), formed
in 1995, published criteria for assessing short-term improvement with
SM-ARDs and was in 2002 working to develop criteria for testing
infliximab and etanercept as DC-ARTs (van der Heijde et al. 2002).
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with a terrain which years of clinical testing had revealed
and make way for stringent testing of the many toxic agents
that were introduced as powerful medicines. As a con-
ceptual reform implicitly directed at ridding rheumatology
of non-efficient drugs, it was an initiative typical to the
early 1990s, when the movement known as evidence-based
medicine (EBM) emerged to strengthen emphasis on sci-
entific testing of the effect of drugs [see for instance Pope
(2003).
Why then did the initiative not succeed? Technical
challenges, complicated procedures and high costs may
have been one factor. But in medicine, complicated proce-
dures and high costs do not alone explain why things do not
happen. Lack of support from powerful groups was a factor,
but rather than providing an answer, the failure of such
groups to embrace the proposal begs the question of why.
And this takes us back to where we started: for the categories
proposed in the early 1990s to be established and used, it
would necessitate that individual actors came to consider
those particular concepts more useful than their alternatives,
not on an elevated level of principles and policies, but in the
particular contexts of their work. This, it seems, they did not.
The failure of the initiative to introduce a more stringent
classification and to adjust the classificatory map with the
terrain that research had revealed underscores the para-
doxical qualities of the DMARD concept, which survived
the attempt to replace it, as both tension ridden and robust. It
also illustrates how the terms used to think and talk about
drugs are the results of complicated processes—processes
where argument, planning and intentional action play a
lesser role than one might expect, and where the pragmatic
potential that each term brings into concrete clinical, sci-
entific, regulatory or economic contexts weighes more, in
the long run, than do the original intentions of those who first
put each concept into words.
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